Tempus, AstraZeneca and Pathos AI ink $200M deal for cancer foundation model – FirstWord Pharma
Tempus, AstraZeneca and Pathos AI ink $200M deal for cancer foundation model FirstWord Pharma Article Source https://firstwordpharma.com/story/5951809
Virtual Machine News Platform
Tempus, AstraZeneca and Pathos AI ink $200M deal for cancer foundation model FirstWord Pharma Article Source https://firstwordpharma.com/story/5951809
00:00 Speaker A Let’s take a look at today’s trending tickers. We got Recursion Pharmaceuticals, Intel, and Five Below. We’re…
London’s AIM All Share Index had another gruelling day as investors continue to try and understand what the future looks…
S&P futures: down 4 points. Nasdaq futures: down 49 points. The S&P 500 futures have fallen by 4 points, the…
Google launches TxGemma, a new AI tool for drug discovery FirstWord Pharma Article Source https://firstwordpharma.com/story/5943015
Pharma 4.0 Market InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Pharma 4.0…
Amazon and Memorial Sloan Kettering Cancer Center leap toward AI-driven drug discovery FirstWord Pharma Article Source https://firstwordpharma.com/story/5936159
These Stocks Moved the Most Today: Trade Desk, AppLovin, Intel, Tesla, Robinhood, Deere, MGM, West Pharma, and More Yahoo Article Source…
Abcuro draws $200M to push muscle weakness drug over the finish line FirstWord Pharma Article Source https://firstwordpharma.com/story/5934611
Servier and Google Cloud commit to five more years of AI-powered R&D FirstWord Pharma Article Source https://firstwordpharma.com/story/5928632